Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
APX3330
APX2009
Nyxol
Scientific Posters and Publications
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Enrolling
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
Partnerships
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Financial Information
Investors
Investors
Overview
News / Events
Overview
Press Releases
Events
Email Alerts
Company Information
Overview
Presentations
Management Team
Contacts
FAQ
Financial Information
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Overview
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Contacts
RSS News Feed
Financial Information
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Latest Financial Results
Q2 2023
Quarter Ended Jun 30, 2023
Earnings Release
PDF
HTML
10-Q
Filing
PDF
HTML
XBRL
ZIP
XLS
HTML
Latest 10-K
View HTML
View PDF
Financials
View the latest financials
Balance Sheet
Income Statement
Cash Flow
Form 8937
VIEW PDF
